iGlarLixi CGM Study in Chinese T2D Individuals After OADs

PHASE4RecruitingINTERVENTIONAL
Enrollment

678

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

September 18, 2026

Study Completion Date

September 18, 2026

Conditions
Type 2 Diabetes (T2D)
Interventions
DRUG

iGlarLixi (insulin glargine/lixisenatide)

"iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector.~There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day:~\- iGlarLixi must not be mixed with other insulins nor diluted."

DRUG

Gla-100 (insulin glargine)

Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.

Trial Locations (1)

100730

RECRUITING

Investigational Site Number: 1560001, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT06671587 - iGlarLixi CGM Study in Chinese T2D Individuals After OADs | Biotech Hunter | Biotech Hunter